- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07601451
Outcomes for Patients Who Preserved Their Fertility as Part of Cancer Treatment at the Center for the Study and Preservation of Eggs and Sperm: MaPreservFerti (MaPreservFerti)
Outcomes for Patients Who Preserved Their Fertility as Part of Cancer Treatment at the Center for the Study and Preservation of Eggs and Sperm (CECOS) in Lyon Between 2010 and 2024: an Assessment of Male Parenthood. MaPreservFerti
Improvements in diagnostic methods and cancer treatments have led to a steady increase in survival rates. The 5-year survival rate for men diagnosed with cancer between the ages of 15 and 39 has exceeded 81%. As a result, quality of life-and in particular, addressing the issue of parenthood-has become essential.
Cancer treatments-surgery, radiation therapy, and chemotherapy-can significantly impair fertility. They may cause sexual dysfunction (anejaculation, anerection), androgen deficiency, or permanent impairment of spermatogenesis. Yet the desire for parenthood ranks among the top three life goals of patients newly diagnosed with cancer, and 50% of patients wish to have a child in the future. Preserving male fertility is therefore a crucial issue.
Before puberty, this can be done by taking a testicular tissue sample, although this is still considered experimental. After puberty, a sample taken from ejaculate allows for the storage of sperm straws.
Thus, when a couple wishes to conceive, following a potential reassessment of spermatogenesis if it is impaired, Assisted Reproductive Technology (ART) can be performed with or without the frozen sperm.
According to the literature, the sperm is typically used within 10 years of fertility preservation. Little data has been collected regarding whether men with a history of cancer conceive naturally or not. It is therefore important to gather this information regarding fatherhood, particularly whether men with a history of cancer have used ART or not, and whether frozen sperm was used or not, based on the results of the follow-up semen analysis performed after treatment.
Primary objective To describe fertility-whether spontaneous or following assisted reproductive technology (ART)-with or without the use of preserved gametes, among patients who underwent fertility preservation for cancer treatment at the CECOS in Lyon between 2010 and 2024.
Secondary objective:
To assess the population of men who preserved their fertility prior to cancer treatment at the Center for the Study and Preservation of Eggs and Sperm (CECOS) in Lyon between 2010 and 2024, specifically:
- The number and clinical and epidemiological characteristics of the patients.
- Describe post-cancer fertility
- Understand CECOS's care protocols to improve the patient care pathway.
- Describe the psychological difficulties at the time of collection that prevented the procedure and thus the preservation of fertility.
- Determine the fate of preserved straws that were not used
Methodology:
- Retrospective analysis of data from the CECOS in Lyon between 2010 and 2024.
- Information collected from the database: patient age, indication, type of fertility preservation performed (testicular tissue or ejaculate)
- Subsequently, a paper and electronic questionnaire was sent to these same patients to collect data on their fertility following fertility preservation.
- Information collected via the questionnaires: marital status, place of residence, paternity prior to cancer, type of cancer, treatment received, achievement of pregnancy after cancer and method (spontaneous pregnancy, reuse of straws at the center, or ART at another center), donation of gametes to research, or destruction if unused.
The CECOS in Lyon is an integral part of the Department of Reproductive Medicine and Biology at the Hopsices Civils de Lyon.
Population studied: This study focuses on patients with a history of cancer who underwent gonadotoxic treatment and preserved their fertility at the CECOS in Lyon between 2010 and 2024
Inclusion criteria:
This study will include patients who:
- were between the ages of 18 and 60 at the time of fertility preservation
- underwent fertility preservation at the CECOS in Lyon between January 1, 2010, and December 31, 2024.
- underwent fertility preservation in the context of cancer treatment
- who have indicated their consent to participate in the study by completing the questionnaire
Exclusion criteria:
- Persons deprived of their liberty by a judicial or administrative decision
- Persons receiving psychiatric care
- Persons admitted to a health or social care facility for purposes other than research
- Adults subject to a legal protection measure (guardianship, conservatorship)
Procedure:
An information sheet will be sent to patients regarding the analysis of their medical data collected during their care, along with a questionnaire (see attached questionnaire) for the collection of prospective data. The materials will be sent either by mail (with a stamped envelope for free return shipping as part of the study) or electronically via a dedicated and secure CECOS email address for email responses.
Number of subjects : 950 Study duration : 1 year
Study location : Center for the Study and Preservation of Eggs and Sperm (CECOS)
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Eloïse FRAISON, Dr
- Telefonnummer: +33 04 72 12 94 12
- E-post: eloise.fraison@chu-lyon.fr
Studiesteder
-
-
France
-
Bron, France, Frankrike, 69500
- CECOS, Hôpital Femme Mère Enfant
-
Ta kontakt med:
- Eloïse FRAISON, Dr
- Telefonnummer: +33 04 72 12 94 12
- E-post: eloise.fraison@chu-lyon.fr
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- were between the ages of 18 and 60 at the time of fertility preservation
- Underwent fertility preservation at the CECOS in Lyon between January 1, 2010, and December 31, 2024.
- underwent fertility preservation in the context of cancer treatment
- who have indicated their consent to participate in the study by completing the questionnaire
Exclusion Criteria:
- Persons deprived of their liberty by a judicial or administrative decision
- Persons receiving psychiatric care
- Persons admitted to a health or social care facility for purposes other than research
- Adults subject to a legal protection measure (guardianship, conservatorship)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Targeted patients
Patients who undergone fertility preservation after gonadotoxic cancer treatments in the Lyon CECOS between 2010 and 2024 will receive a self-assessment form. After completing it they will return it to the center for analysis |
The self-assessment form will be sent only once.
Patients will return it through a pre-stamped envelope joined to the form
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The fertility of patients who underwent fertility preservation for cancer treatment at the CECOS in Lyon between 2010 and 2024.
Tidsramme: Day 1
|
It will be assessed based on the percentage of patients whose partners had a positive pregnancy test:
|
Day 1
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- 69HCL25_0974
- 2025-A02363-46 (Annen identifikator: ID-RCB)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Patient self-assessment form
-
Shifa Tameer-e-Millat UniversityFullført
-
Wake Forest University Health SciencesFullførtSelf Geriatric Assessment Measure (SGAM)Forente stater
-
Namik Kemal UniversityFullførtSelvpleie | Forsørger | Stomi Ileostomi | Stomi KolostomiTyrkia
-
Gazi UniversityHar ikke rekruttert ennåSkulderartroskopi | Kirurg tilfredshetTyrkia
-
University of British ColumbiaFullført
-
Bandırma Onyedi Eylül UniversityFullførtMuskelbiomekanikk | Smarttelefon addisctionTyrkia
-
Superior UniversityAktiv, ikke rekrutterende
-
Oslo University HospitalThe Research Council of NorwayFullførtLymfom | Leukemi | Kreft | Stamcelletransplantasjon
-
Sultan Abdulhamid Han Training and Research Hospital...Har ikke rekruttert ennåBrystkreft | Dysfunksjon i øvre ekstremiteter | VevsvedheftTyrkia
-
University of Southern DenmarkEsbjerg Municipality; Municipality of Slagelse; Municipality of Odense; Christian... og andre samarbeidspartnereFullførtFunksjonshemming FysiskDanmark